Merck Highlights Ongoing Commitment to Fighting Infectious Diseases with More Than 30 Data Presentations at ECCMID 2016
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that researchers are scheduled to provide more than 30
scientific data presentations on the company’s established and
investigational infectious disease medicines and vaccines at this year’s
26th European Congress of Clinical Microbiology and Infectious Diseases
(ECCMID), April 9-12 in Amsterdam, Netherlands.
Language:
English ...
Source: Merck.com - Corporate News - April 7, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK ECCMID Infectious Diseases NYSE:MRK Source Type: news
Merck Receives 2016 ENERGY STAR Sustained Excellence Award From U.S. Environmental Protection Agency
Dateline City:
KENILWORTH, N.J.
Company Receives EPA Honor for 11th Consecutive Year
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that it has received an ENERGY STAR 2016 Partner of the
Year – Sustained Excellence Award from the U.S. Environmental Protection
Agency (EPA) for its continued improvement of energy performance and
leadership in energy management in both the pharmaceutical and
...
Source: Merck.com - Corporate News - April 1, 2016 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News Energy Star EPA Merck MRK MSD Source Type: news
Merck Foundation Awards Grant to American Cancer Society for Program to Improve Access to High-Quality Cancer Care in Underserved Communities
Dateline City:
KENILWORTH, N.J.
$1.58 Million Grant Supports Patient Navigation Program, Empowering Patients and Caregivers with Information and Support
KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (the Foundation) and the American Cancer Society
(ACS) announced today that the Foundation provided a grant of $1.58
million over four years to the ACS to implement a comprehensive Patient
Navigation Program in three U.S. communities where substantial cancer
...
Source: Merck.com - Corporate News - March 24, 2016 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News Source Type: news
MSD Animal Health Receives Positive Final Opinion from European Medicines Agency for BRAVECTO™ (fluralaner) Spot-On for Cats and Dogs
Dateline City:
MADISON, N.J.
Only Spot-On Treatment for Fleas and Ticks Effective For 12 Weeks
MADISON, N.J.--(BUSINESS WIRE)--MSD Animal Health (known as Merck Animal Health in the United States and
Canada) today announced that the Committee for Medicinal Products for
Veterinary Use (CVMP) of the European Medicines Agency has adopted a
positive final opinion, recommending the granting of a marketing
authorization for the veterinary medicinal product BRAVECTO™
(...
Source: Merck.com - Corporate News - March 22, 2016 Category: Pharmaceuticals Tags: Corporate News Animal Health Latest News Source Type: news
Merck Applauds the U.S. Department of Veterans Affairs (VA) for Broadening Treatment Access for Veterans with Chronic Hepatitis C Infection
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
applauds the U.S. Department of Veterans Affairs (VA) for broadening
access to treatment for Veterans with chronic hepatitis C virus (HCV)
infection.
Language:
English
Contact:
MerckMedia:Pam Eisele, 267-305-3558Sarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740...
Source: Merck.com - Corporate News - March 9, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Hepatitis C NYSE:MRK ZEPATIER Source Type: news
Sanofi Pasteur and Merck (Known as MSD Outside the United States and Canada) Announce Intent to End Joint Vaccines Operations in Europe, Sanofi Pasteur MSD, to Pursue Their Own Distinct Growth Strategies
Dateline City:
KENILWORTH, N.J. & LYON, France
KENILWORTH, N.J. & LYON, France--(BUSINESS WIRE)--Sanofi Pasteur and Merck, known as MSD outside the United States and
Canada, today announced their intent to end their joint vaccines
operations in Europe. Upon concluding their joint venture, both
companies plan to integrate their respective European vaccine businesses
into their operations, independently manage their product portfolios and
pursue their own distinct growth strategies in Europe.
Language:
...
Source: Merck.com - Corporate News - March 8, 2016 Category: Pharmaceuticals Tags: Vaccine News Corporate News Latest News #Merck #MRK $MRK MSD NYSE:MRK Sanofi Pasteur Source Type: news
Merck Names Sanat Chattopadhyay President of Merck Manufacturing Division; Will Succeed Willie A. Deese Who Will Retire
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the appointment of Sanat Chattopadhyay as executive vice
president and president, Merck Manufacturing Division (MMD), effective
April 1, 2016. Chattopadhyay will succeed Willie A. Deese who will
retire on June 1, 2016 after 12 years with the company.
Language:
English
Contact:
...
Source: Merck.com - Corporate News - March 7, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK NYSE:MRK Source Type: news
FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Advanced Non-Small Cell Lung Cancer
Dateline City:
KENILWORTH, N.J.
Application Based on Data from KEYNOTE-010, Which Showed Superior Overall Survival for Patients Taking KEYTRUDA Compared to Chemotherapy in Patients with PD-L1 Expression on One Percent or More of the Cancer Cells
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review a new supplemental Biologics...
Source: Merck.com - Corporate News - March 7, 2016 Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News #Merck #MRK $MRK Keytruda NYSE:MRK Source Type: news
Merck and the Mectizan Donation Program Donate $1 Million to the END Fund for Efforts to Help Eliminate River Blindness in Africa
Dateline City:
KENILWORTH, N.J.
Since 1987 Merck Has Donated More than Two Billion Treatments of Mectizan to Help Eliminate River Blindness and Lymphatic Filariasis
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the company, together with the Mectizan Donation
Program, is donating $1 million to the END Fund in support of efforts in
Africa to eliminate river blindness, which is also known as
...
Source: Merck.com - Corporate News - March 4, 2016 Category: Pharmaceuticals Tags: Corporate News Corporate Responsibility News Latest News #Merck #MRK $MRK END Fund Mectizan NYSE:MRK River Blindness Source Type: news
Merck Announces Second-Quarter 2016 Dividend
Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the Board of Directors has declared a quarterly
dividend of $0.46 per share of the company’s common stock for the second
quarter of 2016. Payment will be made on April 7, 2016, to shareholders
of record at the close of business on March 15, 2016.
About Merck
Language:
English
Contact:
...
Source: Merck.com - Corporate News - February 23, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #Merck #MRK $MRK Dividend NYSE:MRK Source Type: news
FDA Approves Merck’s Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection, in Combination with Other Antiemetic Agents, for the Prevention of Delayed Nausea and Vomiting in Adults Receiving Moderately Emetogenic Chemotherapy (MEC)
Dateline City:
KENILWORTH, N.J.
First and Only Intravenous NK1 Receptor Antagonist Approved in the U.S. for Use in MEC
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved a supplemental new drug application (sNDA) for single-dose EMEND®
(fosaprepitant dimeglumine) for injection, Merck’s substance
P/neurokinin-1 (NK1) receptor antago...
Source: Merck.com - Corporate News - February 4, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Emend MSD Source Type: news
Merck Announces Fourth-Quarter and Full-Year 2015 Financial Results
Dateline City:
KENILWORTH, N.J.
Fourth-Quarter 2015 GAAP EPS was $0.35; Fourth-Quarter Non-GAAP EPS was $0.93, an Increase of 7 Percent; Full-Year 2015 GAAP EPS was $1.56; Full-Year 2015 Non-GAAP EPS was $3.59, an Increase of 3 Percent
Fourth-Quarter 2015 Worldwide Sales Were $10.2 Billion, a Decrease of 3 Percent, Including a 7 Percent Negative Impact from Foreign Exchange and 3 Percent Net Favorable Impact from Acquisitions and Divestitures
Full-Year...
Source: Merck.com - Corporate News - February 3, 2016 Category: Pharmaceuticals Tags: Corporate News Financial News Latest News #earnings #Merck #MRK $MRK MSD NYSE:MRK Source Type: news
Merck Receives FDA Approval of ZEPATIER™ (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Genotype 1 or 4 Infection in Adults Following Priority Review
Dateline City:
KENILWORTH, N.J.
ZEPATIER Achieves High Cure Rates (SVR12) in Broad Range of Patients with Chronic Hepatitis C Infection, Including Those with Compensated Cirrhosis, Renal Impairment of Any Degree and HIV-1/HCV Co-infection
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved ZEPATIER™ (elbasvir and grazoprevir) for the ...
Source: Merck.com - Corporate News - January 28, 2016 Category: Pharmaceuticals Tags: Prescription Medicine News Corporate News Latest News #Merck #MRK $MRK Hepatitis NYSE:MRK Source Type: news
Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence
Dateline City:
KENILWORTH, N.J.
FDA Grants Priority Review with Target Action Date of July 23, 2016
Marketing Authorization Application Also Filed with the European Medicines Agency
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
accepted for review the Biologics License Application (BLA) for
bezlotoxumab, an investigational antitoxin f...
Source: Merck.com - Corporate News - January 27, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK Bezlotoxumab ClostridiumDifficile NYSE:MRK Source Type: news
Data for KEYTRUDA® (pembrolizumab) in a Range of Gastrointestinal Cancers to be Presented at 2016 Gastrointestinal Cancers Symposium
Dateline City:
KENILWORTH, N.J.
Seven Registration-Enabling Trials Evaluating KEYTRUDA in Patients with Gastrointestinal Cancers are Planned or Underway
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that new and updated findings investigating the use of
KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy,
in multiple gastrointestinal cancers will be presented at this year’s
Gast...
Source: Merck.com - Corporate News - January 19, 2016 Category: Pharmaceuticals Tags: Corporate News Latest News #Merck #MRK $MRK GI Cancers Symposium NYSE:MRK Source Type: news
